Joshua Richter

Dr. Landgren is Professor of Medicine, Chief of the Myeloma Division, Director of Sylvester Myeloma Institute, Paul J. DiMare Endowed Chair in Immunotherapy, Leader of the Experimental Therapeutics Program, and Co-Leader of the Translational and Clinical Oncology (TCO) Program at NCI-designated Sylvester Comprehensive Cancer Center, part of the University of Miami Health System and Miller School of Medicine. Prior to joining University of Miami, he served as Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York City, and prior to that he was the Chief of the Multiple Myeloma Section at the National Cancer Institute in Bethesda, Maryland. Dr. Landgren is a board-certified hematologist-oncologist and he has published more than 500 papers and chapter books with a primary focus on multiple myeloma, MGUS (monoclonal gammopathy of undetermined significance), and smoldering myeloma. Dr. Landgren’s research focuses the mechanisms underlying progression from precursor disease to frank malignancy, underlying mechanisms of disease response/resistance, role of MRD (minimal residual disease) negativity, biological mechanisms associated with sustained MRD negativity, identification of novel treatment targets, early drug development, and identification of novel biomarkers.

Joshua Richter, MD, FACP is an Associate Professor of Medicine, Haematology and Oncology in the Myeloma Division at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai and the Director of Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai. He completed undergraduate work at Johns Hopkins University and subsequently went on to medical school at New York Medical College, where he completed residency at St. Vincent’s Hospital. Dr Richter completed his haematology/oncology fellowship at the Yale Cancer Center. After completing his fellowship, he worked in the myeloma division at the John Theurer Cancer Center at Hackensack University Medical Center. In 2018 he joined the Myeloma Division at Mount Sinai Hospital. Dr Richter has been published in numerous oncology journals, including The New England Journal of Medicine, Blood and the Journal of Clinical Oncology. He has an interest in immunotherapy, multi-functional antibodies and precision medicine.

Dr. Parekh completed his clinical training in Hematology and Oncology and postdoctoral training in Dr. Ari Melnick’s lab at the Albert Einstein College of Medicine. He is the Director of Myeloma Translational Research and a Professor in Hematology-Oncology and Oncological Sciences at the Icahn School of Medicine at Mount Sinai. Dr. Parekh’s research focuses on the pathogenesis of hematological malignancies and the development of individualized, precision-medicine therapies for these malignancies. His lab uses an integrated systems biology approach to study genome-wide methylation, gene expression, and DNA sequence variation to understand pathogenesis, develop biomarkers and guide personalized therapy in B cell malignancies, particularly Multiple Myeloma and Non-Hodgkin’s lymphoma.

Dr. Mark Bustoros is a physician-scientist whose research focuses on Multiple Myeloma and other Plasma Cell Dyscrasia, including Waldenstrom Macroglobulinemia and Amyloidosis. He is an Assistant Professor at the Department of Hematology and Medical Oncology at Weill Cornell Medicine.
Dr. Bustoros leads the Plasma cell Dyscrasia lab at Weill Cornell Medicine, which focuses on identifying mechanisms of progression in multiple myeloma, either the cell-autonomous or those dependent on the bone marrow niche. His work involves studying genetic and epigenetic alterations that regulate tumor dissemination and the role of the bone marrow niche in disease progression from early precursor stages (MGUS and smoldering myeloma) to active Multiple Myeloma. His lab also studies the mechanisms of therapeutic resistance in relapsed refractory myeloma and identifying new targets and therapeutic approaches that could be effective in specific molecular subtypes of myeloma.

Dr. Bustoros is a member of the American Society of Hematology, the American Association for Cancer Research (AACR), the International Myeloma Society, and the European Hematology Association. He has received multiple awards, such as the Young Investigator Awards from the International Myeloma Society, the AACR- Korean Cancer Association, and the International Workshop of Waldenstrom Macroglobulinemia. He did his post-doctoral training at the Dana-Farber Cancer Institute, where he also became an Instructor of Medicine at Harvard Medical School.

Dr. Landgren is Professor of Medicine, Chief of the Myeloma Division, Director of Sylvester Myeloma Institute, Paul J. DiMare Endowed Chair in Immunotherapy, Leader of the Experimental Therapeutics Program, and Co-Leader of the Translational and Clinical Oncology (TCO) Program at NCI-designated Sylvester Comprehensive Cancer Center, part of the University of Miami Health System and Miller School of Medicine. Prior to joining University of Miami, he served as Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York City, and prior to that he was the Chief of the Multiple Myeloma Section at the National Cancer Institute in Bethesda, Maryland. Dr. Landgren is a board-certified hematologist-oncologist and he has published more than 500 papers and chapter books with a primary focus on multiple myeloma, MGUS (monoclonal gammopathy of undetermined significance), and smoldering myeloma. Dr. Landgren’s research focuses the mechanisms underlying progression from precursor disease to frank malignancy, underlying mechanisms of disease response/resistance, role of MRD (minimal residual disease) negativity, biological mechanisms associated with sustained MRD negativity, identification of novel treatment targets, early drug development, and identification of novel biomarkers.

Dr. Suzanne Lentzsch is Professor of Medicine and Director of the Multiple Myeloma and Amyloidosis Service at Columbia University. For over two decades, she has led clinical and translational research efforts focused on novel therapies for multiple myeloma and AL amyloidosis.

Her pioneering work led to the first-in-human trial of Cael-101, a monoclonal antibody targeting amyloid fibrils. Dr. Lentzsch co-founded Caelum Biosciences to advance the therapy, and the company was later acquired by AstraZeneca. This project exemplifies her ability to translate scientific discoveries into impactful treatments.

In multiple myeloma, she has defined novel mechanisms of bone disease, immune suppression, and oncogenic signaling, leading to clinical trials involving venetoclax and bendamustine. Her research is supported by continuous NIH, LLS, IMS, and CRI funding.

Dr. Lentzsch co-chairs the NCI Myeloma Steering Committee and the International Myeloma Society (IMS) Career Development Committee, where she co-created the IMS Career Development Award. She is passionate about mentoring the next generation of translational scientists.

She serves on the ASH Scientific Committee for Plasma Cell Neoplasia, the ASCO Hematologic Malignancies Program Committee, the SOHO and SWOG Myeloma Working Groups, and on the Scientific Advisory Boards of the MMRF, IMS and Nexcella, Inc. She is Associate Editor for JCO and on the Editorial Board of Blood Cancer Discoveries.

Dr. Lentzsch has published over 180 papers in journals such as Nature Communications, JCI, Blood, Leukemia, and JCO, and remains committed to advancing global standards of care and research for plasma cell disorders.

Joshua Richter, MD, FACP is an Associate Professor of Medicine, Haematology and Oncology in the Myeloma Division at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai and the Director of Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai. He completed undergraduate work at Johns Hopkins University and subsequently went on to medical school at New York Medical College, where he completed residency at St. Vincent’s Hospital. Dr Richter completed his haematology/oncology fellowship at the Yale Cancer Center. After completing his fellowship, he worked in the myeloma division at the John Theurer Cancer Center at Hackensack University Medical Center. In 2018 he joined the Myeloma Division at Mount Sinai Hospital. Dr Richter has been published in numerous oncology journals, including The New England Journal of Medicine, Blood and the Journal of Clinical Oncology. He has an interest in immunotherapy, multi-functional antibodies and precision medicine.

Cesar Rodriguez, MD, is an Associate Professor of Medicine at the Icahn School of Medicine at Mount
Sinai and Clinical Director of the Multiple Myeloma Center of Excellence. He completed training in
Medical Hematology Oncology and did additional specialized training in cancer biology research
and immuniolgy at Harvard Medical School. He focuses on treating patients with plasma cell
disorders using early phase clinical trials and novel immunotherapies such as NK and T-cell redirecting
therapies. He has been an active advocate on health disparities and access of such studies to minorities.
Aside from his patient care, he is performing translational experiments using a three-dimensional
organoid tumor model to study the biology of the myeloma tumor niche and the effects of different
treatment agents as a platform for personalized medicine